108 related articles for article (PubMed ID: 10615243)
1. Antibodies raised by gastrimmune inhibit the spontaneous metastasis of a human colorectal tumour, AP5LV.
Watson SA; Michaeli D; Morris TM; Clarke P; Varro A; Griffin N; Smith A; Justin T; Hardcastle JD
Eur J Cancer; 1999 Aug; 35(8):1286-91. PubMed ID: 10615243
[TBL] [Abstract][Full Text] [Related]
2. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer.
Watson SA; Michaeli D; Grimes S; Morris TM; Robinson G; Varro A; Justin TA; Hardcastle JD
Cancer Res; 1996 Feb; 56(4):880-5. PubMed ID: 8631028
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model.
Watson SA; Michael D; Justin TA; Grimes S; Morris TM; Robinson G; Clarke PA; Hardcastle JD
Int J Cancer; 1998 Mar; 75(6):873-7. PubMed ID: 9506532
[TBL] [Abstract][Full Text] [Related]
4. A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice.
Watson SA; Michaeli D; Grimes S; Morris TM; Varro A; Clarke PA; Smith AM; Justin TA; Hardcastle JD
Int J Cancer; 1999 Apr; 81(2):248-54. PubMed ID: 10188727
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth.
Watson SA; Morris TM; Varro A; Michaeli D; Smith AM
Gut; 1999 Dec; 45(6):812-7. PubMed ID: 10562577
[TBL] [Abstract][Full Text] [Related]
6. Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5.
Watson SA; Michaeli D; Grimes S; Morris TM; Crosbee D; Wilkinson M; Robinson G; Robertson JF; Steele RJ; Hardcastle JD
Int J Cancer; 1995 Apr; 61(2):233-40. PubMed ID: 7705954
[TBL] [Abstract][Full Text] [Related]
7. Gastrimmune-induced antigastrin-17 antibodies inhibit acid secretion in a rat fistula model.
Smith AM; Morris T; Justin T; Michaeli D; Watson SA
Aliment Pharmacol Ther; 2001 Dec; 15(12):1981-8. PubMed ID: 11736730
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer.
Smith AM; Justin T; Michaeli D; Watson SA
Clin Cancer Res; 2000 Dec; 6(12):4719-24. PubMed ID: 11156225
[TBL] [Abstract][Full Text] [Related]
9. Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis.
Watson SA; Smith AM
Cancer Res; 2001 Jan; 61(2):625-31. PubMed ID: 11212260
[TBL] [Abstract][Full Text] [Related]
10. G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy.
Watson SA; Gilliam AD
Expert Opin Biol Ther; 2001 Mar; 1(2):309-17. PubMed ID: 11727538
[TBL] [Abstract][Full Text] [Related]
11. Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT.
BioDrugs; 2003; 17(3):223-5. PubMed ID: 12749761
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer.
Brett BT; Smith SC; Bouvier CV; Michaeli D; Hochhauser D; Davidson BR; Kurzawinski TR; Watkinson AF; Van Someren N; Pounder RE; Caplin ME
J Clin Oncol; 2002 Oct; 20(20):4225-31. PubMed ID: 12377966
[TBL] [Abstract][Full Text] [Related]
13. Antibodies raised against the extracellular tail of the CCKB/gastrin receptor inhibit gastrin-stimulated signalling.
McWilliams DF; Grimes S; Watson SA
Regul Pept; 2001 Jun; 99(2-3):157-61. PubMed ID: 11384777
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of progastrin but not amidated gastrin or glycine extended gastrin are elevated in patients with colorectal carcinoma.
Siddheshwar RK; Gray JC; Kelly SB
Gut; 2001 Jan; 48(1):47-52. PubMed ID: 11115822
[TBL] [Abstract][Full Text] [Related]
15. Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.
Osborne N; Sundseth R; Gay MD; Cao H; Tucker RD; Nadella S; Wang S; Liu X; Kroemer A; Sutton L; Cato A; Smith JP
Am J Physiol Gastrointest Liver Physiol; 2019 Nov; 317(5):G682-G693. PubMed ID: 31433212
[TBL] [Abstract][Full Text] [Related]
16. Designing antibodies for the inhibition of gastrin activity in tumoral cell lines.
Barderas R; Shochat S; Timmerman P; Hollestelle MJ; MartÃnez-Torrecuadrada JL; Höppener JW; Altschuh D; Meloen R; Casal JI
Int J Cancer; 2008 May; 122(10):2351-9. PubMed ID: 18224686
[TBL] [Abstract][Full Text] [Related]
17. Incomplete processing of progastrin expressed by human colon cancer cells: role of noncarboxyamidated gastrins.
Singh P; Xu Z; Dai B; Rajaraman S; Rubin N; Dhruva B
Am J Physiol; 1994 Mar; 266(3 Pt 1):G459-68. PubMed ID: 8166285
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of proliferation and migration of a colorectal cancer cell line by amidated and glycine-extended gastrin-releasing peptide via the same receptor.
Patel O; Dumesny C; Giraud AS; Baldwin GS; Shulkes A
Biochem Pharmacol; 2004 Dec; 68(11):2129-42. PubMed ID: 15498503
[TBL] [Abstract][Full Text] [Related]
19. Identification of progastrin derived peptides in colorectal carcinoma extracts.
Nemeth J; Taylor B; Pauwels S; Varro A; Dockray GJ
Gut; 1993 Jan; 34(1):90-5. PubMed ID: 8432459
[TBL] [Abstract][Full Text] [Related]
20. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin.
Watson SA; Durrant LG; Crosbie JD; Morris DL
Int J Cancer; 1989 Apr; 43(4):692-6. PubMed ID: 2703274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
